Olema Pharmaceuticals Inc’s recently made public that its 10% Owner Paradigm Biocapital Advisors L unloaded Company’s shares for reported $35.8 million on Aug 01 ’24. In the deal valued at $14.91 per share,2,400,000 shares were sold. As a result of this transaction, Paradigm Biocapital Advisors L now holds 783,118 shares worth roughly $8.0 million.
Then, Harmon Cyrus sold 4,066 shares, generating $63,348 in total proceeds. Upon selling the shares at $15.58, the Director now owns 752,217 shares.
Before that, Harmon Cyrus sold 934 shares. Olema Pharmaceuticals Inc shares valued at $14,524 were divested by the Director at a price of $15.55 per share. As a result of the transaction, Harmon Cyrus now holds 751,283 shares, worth roughly $7.67 million.
Goldman initiated its Olema Pharmaceuticals Inc [OLMA] rating to a Buy in a research note published on April 02, 2024; the price target was $24. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. Oppenheimer began covering OLMA with “an Outperform” recommendation on July 21, 2023. CapitalOne started covering the stock on May 05, 2023. It rated OLMA as “an Overweight”.
Price Performance Review of OLMA
On Monday, Olema Pharmaceuticals Inc [NASDAQ:OLMA] saw its stock jump 0.89% to $10.21. Over the last five days, the stock has gained 16.29%. Olema Pharmaceuticals Inc shares have fallen nearly -27.23% since the year began. Nevertheless, the stocks have fallen -26.81% over the past one year. While a 52-week high of $16.77 was reached on 02/13/24, a 52-week low of $7.68 was recorded on 11/21/24. SMA at 50 days reached $11.30, while 200 days put it at $11.81.
Levels Of Support And Resistance For OLMA Stock
The 24-hour chart illustrates a support level at 9.58, which if violated will result in even more drops to 8.95. On the upside, there is a resistance level at 10.77. A further resistance level may holdings at 11.34. The Relative Strength Index (RSI) on the 14-day chart is 47.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 50.34%. Stochastics %K at 46.82% indicates the stock is a holding.
How much short interest is there in Olema Pharmaceuticals Inc?
A steep rise in short interest was recorded in Olema Pharmaceuticals Inc stocks on 2024-11-15, growing by 67032.0 shares to a total of 8.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 8.5 million shares. There was a rise of 0.78%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 22, 2023 when Credit Suisse began covering the stock and recommended ‘”an Outperform”‘ rating along with a $12 price target.
